163 related articles for article (PubMed ID: 34725049)
21. The challenge of new classification criteria for axial spondyloarthritis.
Khan MA; Yong SB; van der Linden S
Int J Rheum Dis; 2023 Jul; 26(7):1225-1226. PubMed ID: 37394892
[No Abstract] [Full Text] [Related]
22. Exploring the latest advances in axial spondyloarthritis management.
Benavent D; Navarro-Compán V
Nat Rev Rheumatol; 2024 Feb; 20(2):79-80. PubMed ID: 38191700
[No Abstract] [Full Text] [Related]
23. No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?
Braun J; Landewé RB
Ann Rheum Dis; 2022 Apr; 81(4):466-468. PubMed ID: 34656991
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis.
Webers C; Ortolan A; Sepriano A; Falzon L; Baraliakos X; Landewé RBM; Ramiro S; van der Heijde D; Nikiphorou E
Ann Rheum Dis; 2023 Jan; 82(1):130-141. PubMed ID: 36270657
[TBL] [Abstract][Full Text] [Related]
25. Update on Axial Spondyloarthritis.
Winkler AE; Miller M
Mo Med; 2022; 119(1):79-83. PubMed ID: 36033135
[TBL] [Abstract][Full Text] [Related]
26. [To stress the importance of physical function on treat-to-target in axial spondyloarthritis].
Liu XK; Huang F
Zhonghua Nei Ke Za Zhi; 2023 Feb; 62(2):125-128. PubMed ID: 36740403
[TBL] [Abstract][Full Text] [Related]
27. Response to: "Interleukin-23 Blockade Is Not Effective in Axial Spondyloarthritis".
Peters E; Chou RC; Rozzo SJ; Yao SL; García Fructuoso FJ
J Clin Rheumatol; 2024 Mar; 30(2):e73. PubMed ID: 37678360
[No Abstract] [Full Text] [Related]
28. Etanercept in axial spondyloarthritis.
Luo G; Zhu J
Chin Med J (Engl); 2022 Nov; 135(21):2628-2630. PubMed ID: 35261349
[No Abstract] [Full Text] [Related]
29. Response to: 'Correspondence on 'Which factors are associated with bone marrow oedema suspicious of axial spondyloarthritis as detected by MRI in the sacroiliac joints and the spine in the general population?' by Su
Baraliakos X; Richter A; Schmidt CO; Braun J
Ann Rheum Dis; 2023 Jul; 82(7):e171. PubMed ID: 34001516
[No Abstract] [Full Text] [Related]
30. Characterization of mucosal-associated invariant T cells in blood of patients with axial spondyloarthritis and in axial entheses of healthy controls: comment on the article by Rosine et al.
Toussirot E; Laheurte C; Saas P
Arthritis Rheumatol; 2022 Dec; 74(12):2045-2046. PubMed ID: 35762820
[No Abstract] [Full Text] [Related]
31. Interleukin-23 Blockade Is Not Effective in Axial Spondyloarthritis.
Wendling D
J Clin Rheumatol; 2024 Mar; 30(2):e72. PubMed ID: 37678285
[No Abstract] [Full Text] [Related]
32. Treatment persistence of tumour necrosis factors and IL-17 inhibitors in axial spondyloarthritis: A multi-center comparative analysis.
Delépine T; Philippe P; Cailliau E; Houvenagel E; Pascart T; Deprez X; Flipo RM; Letarouilly JG
Joint Bone Spine; 2022 Nov; 89(6):105416. PubMed ID: 35636707
[No Abstract] [Full Text] [Related]
33. Impact of Axial Spondyloarthritis on Quality of Life: Results From the European Map of Axial Spondyloarthritis (EMAS) Study in France.
Kedra J; Claudepierre P; Flipo RM; Garrido-Cumbrera M; Alliot-Launois F; Desfleurs E; Grange L; Gossec L
J Rheumatol; 2022 Oct; 49(10):1176-1178. PubMed ID: 35569828
[No Abstract] [Full Text] [Related]
34. Response to: 'Correspondence on 'Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial'' by Zhao and Huang.
Wei JC; Kim TH; Kishimoto M; Ogusu N; Jeong H; Kobayashi S
Ann Rheum Dis; 2023 Jul; 82(7):e169. PubMed ID: 34172504
[No Abstract] [Full Text] [Related]
35. Correspondence on: The effects of physical exercise on axial spondyloarthritis - a systematic review.
Pimentel G; Duarte-Fernandes R; Ferreira RJO
ARP Rheumatol; 2024; 3(1):75-76. PubMed ID: 38557830
[No Abstract] [Full Text] [Related]
36. Novel therapies in axial spondyloarthritis.
Bittar M; Mease P
Best Pract Res Clin Rheumatol; 2022 Dec; 36(4):101811. PubMed ID: 36566165
[TBL] [Abstract][Full Text] [Related]
37. Correspondence on: The effects of physical exercise on axial spondyloarthritis - a systematic review - REPLY.
Santos ME; Gonçalves NP; Silvério-António M; Donato H; Pimentel-Santos F; Cruz E
ARP Rheumatol; 2024; 3(1):77-78. PubMed ID: 38557481
[No Abstract] [Full Text] [Related]
38. Spondyloarthritis mass cytometry immuno-monitoring: a proof of concept study in the tight-control and treat-to target TiCoSpA trial.
Koppejan H; Beyrend G; Hameetman M; Abdelaal T; Toes REM; van Gaalen FA
Clin Rheumatol; 2023 Sep; 42(9):2387-2396. PubMed ID: 37306812
[TBL] [Abstract][Full Text] [Related]
39. Role of Metrology in Axial Spondyloarthritis: Does It Provide Unique Information in Assessing Patients and Predicting Outcome? Results From the British Society for Rheumatology Biologic Register for Ankylosing Spondylitis.
Biallas RL; Dean LE; Davidson L; Hollick R; Pathan E; Robertson L; Jones GT; Macfarlane GJ; Rotariu O
Arthritis Care Res (Hoboken); 2022 Apr; 74(4):665-674. PubMed ID: 33140891
[TBL] [Abstract][Full Text] [Related]
40. Treat-to-target dose reduction and withdrawal strategy of TNF inhibitors in psoriatic arthritis and axial spondyloarthritis: a randomised controlled non-inferiority trial.
Michielsens CA; den Broeder N; van den Hoogen FH; Mahler EA; Teerenstra S; van der Heijde D; Verhoef LM; den Broeder AA
Ann Rheum Dis; 2022 Oct; 81(10):1392-1399. PubMed ID: 35701155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
